title: Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
abstract: Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system. Over the last two decades, the number of therapeutic options for the treatment of relapsing remitting MS (RRMS) has been constantly growing, providing new treatment options to patients. Areas covered: Herein, the authors review the recently approved monoclonal antibody daclizumab for the treatment of RRMS. Based on original articles, they discuss its mode of action and evaluate its efficacy and safety profile compared to other available agents. Expert opinion: The IL-2 receptor modulator daclizumab is a new highly effective agent for the treatment of RRMS with novel immunomodulatory properties. Compared to interferon-beta i.m., daclizumab is more effective in reducing relapse rates and MRI activity. However, its use is limited by the risk of autoimmune disorders and hepatotoxicity. Similar to other monoclonal antibodies for RRMS, therapy with daclizumab needs a strict preselection and monitoring of patients based on individual risk benefit assessment. Given its substantial effectiveness, daclizumab can be an attractive option for patients with highly active MS.
authors.affiliation: a Department of Neurology , Klinikum rechts der Isar, Technical University of Munich , Munich , Germany.|b Institute of Neuronal Cell Biology , Technical University of Munich , Munich , Germany.
authors.forename: Marina
authors.initials: M
authors.lastname: Herwerth
authors.affiliation: a Department of Neurology , Klinikum rechts der Isar, Technical University of Munich , Munich , Germany.|c Munich Cluster for Systems Neurology (SyNergy) , Munich , Germany.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hemmer
mesh_terms: D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D056747:Immunomodulation; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015375:Receptors, Interleukin-2 / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab
keywords: Antibody; daclizumab; disability; interleukin-2 receptor; multiple sclerosis; natural killer cells; opinion; therapy